Multiple endocrine neoplasia type 1 is an autosomal dominant cancer syndrome characterized by pituitary, parathyroid and enteropancreatic endocrine tumors, which is caused by germline mutations of the tumor suppressor gene MEN1. In the case reported here, the patient had family with this disease whose germline MEN1 mutation was undetectable by conventional sequencing analysis. Further investigations involving polymorphism analyses, gene dose assay and nucleotide sequencing identified a large germline deletion of approximately 29 kilobase pairs spanning the whole MEN1 gene. The deletion was flanked by Alu repetitive sequences, suggesting unequal homologous recombination as the deletion mechanism. The polymorphism linkage data suggested that an asymptomatic son of the proband did not carry the family mutation. More direct evidence was obtained by gene dose assay and deletion-specific polymerase chain reaction, which demonstrated the normal MEN1 gene dosage and the absence of the deletion breakpoints in this asymptomatic subject and thus definitely excluded the possibility of disease predisposition.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyl089DOI Listing

Publication Analysis

Top Keywords

men1 gene
12
gene deletion
8
deletion flanked
8
flanked alu
8
multiple endocrine
8
endocrine neoplasia
8
neoplasia type
8
gene dose
8
dose assay
8
men1
5

Similar Publications

Article Synopsis
  • Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic disorder characterized by tumors in multiple endocrine glands, but some patients may lack the genetic markers typically associated with the condition.
  • A 56-year-old woman with a history of a macroprolactinoma, primary hyperparathyroidism, and a cortisol-producing adrenal adenoma was diagnosed with MEN1 despite being genotype-negative, raising concerns about the reliability of genetic testing.
  • The case highlights that genotype-negative MEN1 can involve serious complications and emphasizes the importance of recognizing clinical symptoms like glucose intolerance and tumor manifestations to avoid delayed diagnoses.
View Article and Find Full Text PDF

Alternative splicing generates isoform diversity in .

Endocr Oncol

January 2024

Department of Molecular Medicine and Pathology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Although the gene has a long-standing association with cancer, its mechanisms of action remain incompletely understood, acting both as a tumour suppressor in neuroendocrine tumours and as an oncogene in leukaemia. The best-characterised isoform of the encoded protein, MENIN, is the 610-amino acid MENIN isoform 2. We hypothesise that some of the complexity of biology can be attributed to a currently unappreciated contribution of different MENIN isoforms.

View Article and Find Full Text PDF

Genotype-based prognosis prediction for MEN1-Related pancreatic neuroendocrine tumors in Korean patients a single-center retrospective study.

Pancreatology

November 2024

Pancreatobiliary Cancer Center, Yonsei Cancer Center, Severance Hospital, Seoul, South Korea; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea. Electronic address:

Background: Pancreatic neuroendocrine tumors (PNETs) are the leading cause of death related to multiple endocrine neoplasia type 1 (MEN1). Previous studies have linked certain mutations in the MEN1 gene and loss of interactions with MENIN's functional partners to the mortality or aggressiveness of PNETs. This study aimed to evaluate the genotype-phenotype correlations of MEN1-related PNETs in Korean patients and to summarize the treatment outcomes comprehensively.

View Article and Find Full Text PDF

Multiple endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome characterized by endocrine tumors, typically from parathyroid, pancreatic, or anterior pituitary origin. In addition, benign cutaneous soft tissue tumors are prevalent in MEN1 patients. Although sarcomas have been reported in MEN1 patients it is unclear if these tumors should be considered as part of the MEN1 syndrome.

View Article and Find Full Text PDF

Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions.

Cancers (Basel)

November 2024

Department of Oncology, Karmanos Cancer Center, School of Medicine, Wayne State University, Detroit, MI 48201, USA.

Germline mutations in the gene encoding menin protein cause multiple endocrine neoplasia type 1 (MEN1) syndrome. Recent evidence suggests that inhibiting the interaction of menin with its crucial oncogenic protein partners represents a promising therapeutic strategy to AML. Menin plays a critical role in lysine methyltransferase 2A ()-gene-rearranged and -m acute leukemias, both associated with adverse outcomes with current standard therapies, especially in the relapsed/refractory setting.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!